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The three-dimensional structure of adeno-associated virus (AAV) serotype 6 (AAV6) was determined using
cryo-electron microscopy and image reconstruction and using X-ray crystallography to 9.7- and 3.0-Å resolu-
tion, respectively. The AAV6 capsid contains a highly conserved, eight-stranded (B to I) -barrel core and
large loop regions between the strands which form the capsid surface, as observed in other AAV structures. The
loops show conformational variation compared to other AAVs, consistent with previous reports that amino
acids in these loop regions are involved in differentiating AAV receptor binding, transduction efficiency, and
antigenicity properties. Toward structure-function annotation of AAV6 with respect to its unique dual glycan
receptor (heparan sulfate and sialic acid) utilization for cellular recognition, and its enhanced lung epithelial
transduction compared to other AAVs, the capsid structure was compared to that of AAV1, which binds sialic
acid and differs from AAV6 in only 6 out of 736 amino acids. Five of these residues are located at or close to
the icosahedral 3-fold axis of the capsid, thereby identifying this region as imparting important functions, such
as receptor attachment and transduction phenotype. Two of the five observed amino acids are located in the
capsid interior, suggesting that differential AAV infection properties are also controlled by postentry intra-
cellular events. Density ordered inside the capsid, under the 3-fold axis in a previously reported, conserved
AAV DNA binding pocket, was modeled as a nucleotide and a base, further implicating this capsid region in
AAV genome recognition and/or stabilization.
Adeno-associated viruses (AAVs) are nonpathogenic single-
stranded DNA (ssDNA) parvoviruses that belong to the De-
pendovirus genus and require helper viruses, such as Adenovi-
rus or Herpesvirus, for lytic infection (4, 8, 22, 67). These
viruses package a genome of 4.7 kb inside an icosahedral
capsid (260 Å in diameter) with a triangulation number
equal to 1 assembled from a total of 60 copies of their over-
lapping capsid viral protein (VP) 1 (VP1), VP2, and VP3 in a
predicted ratio of 1:1:8/10 (10). The VPs are encoded from a
cap open reading frame (ORF). VP3 is 61 kDa and constitutes
90% of the capsid’s protein composition. The less abundant
VPs, VP1 (87 kDa) and VP2 (73 kDa), share the same C-
terminal amino acid sequence with VP3 but have additional
N-terminal sequences. A rep ORF codes for four overlapping
proteins required for replication and DNA packaging.
To date, more than 100 AAV isolates have been identified
(21). Among the human and nonhuman primate AAVs iso-
lated, 12 serotypes (AAV serotype 1 [AAV1] to AAV12) have
been described and are classified into six phylogenetic clades
on the basis of their VP sequences and antigenic reactivities,
with AAV4 and AAV5 considered to be clonal isolates (21).
AAV1 and AAV6, which represent clade A, differ by only 6 out
of 736 VP1 amino acids (5 amino acids within VP3) and are
antigenically cross-reactive. Other clade representatives in-
clude AAV2 (clade B), AAV2-AAV3 hybrid (clade C), AAV7
(clade D), AAV8 (clade E), and AAV9 (clade F) (21).
The AAVs are under development as clinical gene delivery
vectors (e.g., see references 5, 9, 12, 13, 24, 25, 53, and 61), with
AAV2, the prototype member of the genus, being the most
extensively studied serotype for this application. AAV2 has
been successfully used to treat several disorders, but its broad
tissue tropism makes it less effective for tissue-specific appli-
cations and the prevalence of preexisting neutralizing antibod-
ies in the human population (11, 43) limits its utilization, es-
pecially when readministration is required to achieve a
therapeutic outcome. Efforts have thus focused on character-
izing the capsid-associated tissue tropism and transduction
properties conferred by the capsid of representative serotypes
of other clades (21). Outcomes of these studies include the
observation that AAV1 and AAV6, for example, transduce
liver, muscle, and airway epithelial cells more efficiently (e.g.,
up to 200-fold) than AAV2 (27, 28, 30). In addition, the six
residues (Table 1) that differ between the VPs of AAV1 and
AAV6 (a natural recombinant of AAV1 and AAV2 [56]) con-
fer functional disparity between these two viruses. For exam-
ple, AAV6 shows 3-fold higher lung cell epithelium trans-
duction than AAV1 (27), and AAV1 and AAV6 bind
terminally sialylated proteoglycans as their primary receptor,
whereas AAV6 additionally binds to heparan sulfate (HS) pro-
teoglycans with moderate affinity (70, 71). Therefore, a com-
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parison of the AAV1 and AAV6 serotypes and, in particular,
their capsid structures can help pinpoint the capsid regions
that confer differences in cellular recognition and tissue trans-
duction.
The structures of AAV1 to AAV5 and AAV8 have been
determined by X-ray crystallography and/or cryo-electron mi-
croscopy and image reconstruction (cryo-EM) (23, 36, 47, 52,
66, 73; unpublished data), and preliminary characterization of
crystals has also been reported for AAV1, AAV5, AAV7, and
AAV9 (15, 45, 46, 55). The capsid VP structures contain a
conserved eight-stranded (B to I) -barrel core and large
loop regions between the strands that form the capsid surface.
The capsid surface is characterized by depressions at the ico-
sahedral 2-fold axes of symmetry, finger-like projections sur-
rounding the 3-fold axes, and canyon-like depressions sur-
rounding the 5-fold axes. A total of nine variable regions (VRs;
VRI to VRIX) were defined when the two most disparate
structures, AAV2 and AAV4, were compared (23). The VRs
contain amino acids that contribute to slight differences in
surface topologies and distinct functional phenotypes, such as
in receptor binding, transduction efficiency, and antigenic re-
activity (10, 23, 37, 47).
The structure of virus-like particles (VLPs) of AAV6,
produced in a baculovirus/Sf9 insect cell expression system,
has been determined by two highly complementary ap-
proaches, cryo-EM and X-ray crystallography. The AAV6
VP structure contains the general features already described
for the AAVs and has conformational differences in the VRs
compared to the VRs of other AAVs. The 9.7-Å-resolution
cryoreconstructed structure enabled the localization of the
C- positions of five of the six amino acids that differ be-
tween highly homologous AAV6 and AAV1 but did not
provide information on the positions of the side chains or
their orientations. The X-ray crystal structure determined to
3.0-Å resolution enabled us to precisely map the atomic
positions of these five residues at or close to the icosahedral
3-fold axes of the capsid. Reported mutagenesis and bio-
chemical studies had functionally annotated the six residues
differing between AAV1 and AAV6 with respect to their
roles in receptor attachment and differential cellular trans-
duction. Their disposition identifies the 3-fold capsid region
as playing essential roles in AAV infection.
MATERIALS AND METHODS
Production and purification of AAV6 VLPs. A recombinant baculovirus en-
coding VP2 and VP3 of AAV6 was constructed using the Bac-to-Bac system
(Gibco/Invitrogen Corporation), as described previously for AAV1 and AAV5
but with an inserted AAV6 cap ORF. DH10Bac competent cells containing the
baculovirus genome were transformed with pFastBac transfer plasmids contain-
ing the AAV component insert. Bacmid DNA purified from recombination-
positive white colonies was transfected into Sf9 cells using Cellfectin reagent
(Gibco/Invitrogen Corporation). At 3 days posttransfection, media containing
recombinant AAV6 baculovirus were harvested and plaque assays were con-
ducted to prepare independent plaque isolates. Several individual plaques were
propagated to passage one (P1) to evaluate the levels of VP2 and VP3 expres-
sion. The clone with the highest level of protein expression was propagated to P2
and then P3 for VLP production.
Sf9 insect cells cultured in Sf900 II serum-free medium (Gibco/Invitrogen Cor-
poration) were infected at a multiplicity of infection of 5.0 PFU/cell with a recom-
binant AAV6 baculovirus expressing VP2 and VP3 whose titer had been determined
(P3 stock). AAV6 VLPs were released from infected cells by three freeze-thaw
cycles in lysis buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA,
0.2% Triton X-100), with benzonase (Merck, Germany) being added after the
second cycle. The sample was clarified by centrifugation at 12,100  g at 4°C for
15 min. Next, the cell lysate was pelleted through a 20% (wt/vol) sucrose cushion
in TNET buffer (25 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.06%
Triton X-100) by ultracentrifugation at 149,000  g at 4°C for 3 h. The pellet
from the sucrose cushion was resuspended in TNTM buffer (50 mM Tris-HCl,
pH 8.0, 100 mM NaCl, 0.06% Triton X-100, 30 mM MgCl2) overnight at 4°C.
The sample was clarified by several rounds of centrifugation at 10,000  g to
remove insoluble material. The clarified sample was loaded onto a sucrose step
gradient (5 to 40% [wt/vol]) and spun at 151,000  g at 4°C for 3 h. A visible blue
virus band was extracted from the 20/25% sucrose layer and dialyzed into 20 mM
Tris-HCl (pH 7.5), 2 mM MgCl2, and 350 mM NaCl at 4°C. The approximate
VLP concentration (in mg/ml) was calculated on the basis of optical density
measurements at 280 nm, assuming an extinction coefficient of 1.7. The purity
and integrity of the VLPs were monitored using SDS-PAGE and negative-stain
electron microscopy (EM), respectively.
Structure determination of AAV6 VLPs by cryo-EM. Small (3.5-l) aliquots of
purified VLPs (10 mg/ml) were vitrified via standard rapid freeze-plunging
procedures [2, 17]). Samples were applied to glow-discharged (15 s in an
Emitech K350 glow-discharge unit) Quantifoil holey grids, blotted for 5 s,
plunged into liquid ethane, and transferred to liquid nitrogen and then into a
precooled Gatan 626 cryospecimen holder. Images of vitrified specimens were
recorded in an FEI Sphera microscope (200 keV, equipped with a LaB6 electron
gun) at 50,000 nominal magnification. Eighteen micrographs with minimal
astigmatism and specimen drift recorded with the objective lens underfocused by
1.0 to 2.5 m were digitized at 7-m intervals (representing 1.4-Å pixels) on a
Zeiss SCAI scanner. A total of 1,870 particles were extracted and preprocessed,
and their defocus levels were estimated using the RobEM program (http:
//cryoEM.ucsd.edu/programs.shtm). The AUTO3DEM program (74) was used
as previously described (26) to combine these particle images and reconstruct the
structure of the AAV6 VLPs. To compensate for the effects of phase reversals in
TABLE 1. Amino acid differences between AAV1 and AAV6 and their reported mutants
AAV
Amino acid at positiona:
Glycan targetb Reference
129 418 531 532 584 598 642
AAV1 L E E D F A N S 70
AAV1-E/K L E K D F A N HS (and S)c 70
AAV6 F D K D L V H HS and S 70
AAV6.1 F D E D L V H HS (and S)c 40, 70
AAV6.2 L D K D L V H HS (and S)c 40, 70
AAV6R2 L D E D L V H HS (and S)c 40
HAE1 L E E D L V N (HS and S)d 39
HAE2 L D K D L V N (HS and S)d 39
shH10 F D K N L V N HS (and S-inde) 33
a Mutant residues in boldface have an AAV6 parental original; those underlined have an AAV1 parental origin.
b S, sialic acid; HS, heparan sulfate; HS, HS positive.
c The sialic acid binding phenotypes of these mutants were not discussed in the respective publications but are assumed to be still present.
d The glycan targets for these mutants were not discussed in this publication; thus, the phenotypes indicated are assumed.
e This mutant is sialic acid independent (S-ind) for cellular transduction.
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the contrast-transfer function of the images, phase corrections were performed
but no amplitude corrections were applied. A conservative Fourier shell corre-
lation of 0.5 was used as the threshold for estimating the resolution of the
cryoreconstructed structure (65). The available coordinates for an AAV1 VP3
polyalanine capsid model (amino acids [aa] 218 to 736, VP1 numbering), ex-
tracted from a recently determined X-ray crystal structure (L. Govindasamy and
M. Agbandje-McKenna, unpublished data), were docked into the AAV6 cryore-
construction using the Situs package (68) for pseudoatomic model interpretation
of the density map. The cryoreconstructed map and docked model were visual-
ized in the Chimera program (54).
Structure determination of AAV6 VLPs by X-ray crystallography. Crystals
were grown from purified VLPs in 100 mM HEPES, pH 7.3, at a concentration
of 10.0 mg/ml using the method of hanging-drop vapor diffusion with 60 mM
MgCl2 and 100 mM NaCl as additives, 4% polyethylene glycol 6000 as a precip-
itant, and 25% glycerol as the cryoprotectant. X-ray diffraction data were col-
lected from a single crystal at the Cornell High-Energy Synchrotron Source
(CHESS) with a crystal-to-detector distance of 350 mm, an oscillation angle of
0.3° per image, and an exposure time of 50 s per image. The data were indexed,
processed, scaled, and reduced using the HKL-2000 package (51) (Table 2). The
crystal diffracted X-rays to a 3.0-Å resolution and was determined to be in the
rhombohedral crystal system and space group R32 with unit-cell parameters of a
equal to 262.6 Å and c equal to 609.9 Å (in the hexagonal setting). The data
collection and processing statistics are given in Table 2.
The orientation of the AAV6 VLPs in the crystal unit cell was determined
using the self-rotation function in the General Lock Rotation Function (GLRF)
program (63) with  equal to 72°, 120°, and 180° in the search for icosahedral 2,
3-, and 5-fold-symmetry axes, respectively, with observed data being in the 10.0-
to 5.0-Å resolution range. The crystallographic 2- and 3-fold-symmetry operators
were shown to be coincident with icosahedral symmetry operators, resulting in 10
VPs (noncrystallographic symmetry [NCS] operators) per crystallographic asym-
metric unit of the R32 space group.
The diffraction data were phased using the molecular replacement method in
the AMoRe program (48). The orientation and position of the AAV6 10-mer in
the crystal unit cell were determined by cross-rotation and translation searches,
respectively, using atomic coordinates for 10 AAV1 VP3 monomers (a 10-mer of
residues 218 to 736, VP1 numbering) from a recently determined crystal struc-
ture (Govindasamy and Agbandje-McKenna, unpublished), with the amino acids
within VP3 that differ from those in AAV6, i.e., E418, E531, F584, A598, and
N642, being computationally changed to alanine to eliminate model phase bias.
This VP3 10-mer model was oriented and positioned into the AAV6 crystal unit
cell, on the basis of the output rotation angles, and positioned at (0, 0, 0), on the
basis of space group packing considerations, to calculate a set of initial phases.
These phases were improved by refinement using the Crystallography and NMR
(nuclear magnetic resonance) system (CNS) package (6, 7), using simulated
annealing, energy minimization, atomic position, and temperature factor refine-
ment and with the application of strict NCS operators. A single cycle of electron-
density Fourier map (2Fo  Fc and Fo  Fc, in which Fo represents the observed
structure factors and Fc represents those calculated from the model) averaging
was carried out in CNS, while maintaining strict NCS operators (6, 7), using the
experimentally measured amplitudes and the improved phases following each
model refinement cycle. The refinement and averaging procedures were alter-
nated with model building, using the Coot program (18), into averaged electron-
density maps. To improve the quality of the maps between refinement steps,
density map modification was carried out using the Density Modification sub-
routine in the CCP4 program (3), which performed histogram matching, solvent
flattening, and NCS averaging.
Following the building of VP3 common amino acids 218 to 736 into the av-
eraged density maps, two regions of unassigned densities were observed in the Fo 
Fc density map (at a contour threshold of 3.0 standard deviations [	]) in the
interior of the capsid. A purine nucleotide (NT) and a pyrimidine base were
modeled into these unassigned densities. The resolution of the icosahedrally
averaged map (3.0 Å) was insufficient to determine unambiguously the identities
of the purine and pyrimidine bases. However, there were no amino side group
density observed at the C-2 position of the purine ring and no methyl group
density observed at the C-5 position of the pyrimidine ring; thus, the base
densities were interpreted as adenosine and cytosine, respectively. An occupancy
of 0.5 was determined for each of the two bases by means of an empirical
approach in which values (1.0 to 0.3) were applied to achieve temperature factors
that were comparable with those of the average VP3 amino acid atoms (Table 2).
Finally, 12 solvent molecules were built into remaining averaged positive Fo  Fc
density at 3.0	.
The refined structure had Rcryst (where Rcryst 
 Fobs  Fcalc/Fobs 
100, where Fobs and Fcalc are the amplitudes for the observed and calculated
reflections, respectively) and Rfree values of 27.5% and 28.8%, respectively, and
final root mean square deviations (RMSDs) of 0.009 Å for bond lengths and
1.48° for bond angles. These values are within the range of those for structures
reported at a comparable resolution, as calculated by the Polygon subroutine (62,
64) in the program PHENIX (Python-based Hierarchical Environment for In-
tegrated Xtallography) (1). The quality of the refined structure was analyzed
using the Coot (18) and MOLPROBITY (42) programs. A Ramachandran plot
showed values of 92.5% and 7.5% in the most favorably and additionally allowed
regions, respectively. The refined VP3 coordinates were retrospectively fitted
into the cryoreconstructed AAV6 density map without any main-chain adjust-
ments, as was the case for the AAV1-based model.
Structural comparison of AAV6 VLP to other AAV structures. The refined
AAV6 VP3 structure was compared to the VP3 structures of AAV1 (Govin-
dasamy and Agbandje-McKenna, unpublished), AAV2 (Protein Data Bank
[PDB] accession no. 1LP3), AAV3b (PDB accession no. 3KIC), AAV4 (PDB
accession no. 2G8G), and AAV8 (PDB accession no. 2QA0) by structural align-
ment with the secondary structure matching (SSM) subroutine in the Coot
program (18). The program superimposes C- positions and provides informa-
tion on residues that are structurally equivalent, inserts gaps when the atoms are
too far apart to superimpose, and provides the distances (in Å) between the C-
positions. VRs were identified, as previously defined (23), as containing stretches
of two or more than two amino acids with C- positions that are 1.0 Å apart
between two serotypes.
Protein structure accession number. The refined coordinates and structure
factors for the AAV6 VP3 structure at 3.0-Å resolution have been deposited in
the RCSB PDB with accession number 3OAH.
RESULTS AND DISCUSSION
Structure of AAV6 VLP. The structure of the AAV6 VLP
was determined to 9.7-Å resolution by cryo-EM. The capsid
surface of the reconstructed AAV6 structure exhibits the pre-
viously defined characteristic features of AAV capsids, with a
depression at each 2-fold axis, protrusions surrounding each
3-fold axis, and a canyon-like depression surrounding the chan-
nel at each 5-fold axis (Fig. 1A and B). Consistent with the high
degree of structural similarity between AAV1 and AAV6, a
correlation coefficient of 0.94 was calculated for the fit between
TABLE 2. Data collection and processing statisticsa
Data collection CHESS F1
Wavelength (, Å) ..................................................0.917
Space group .............................................................R32:H
Unit cell parameters (Å) .......................................a 
 262.6, c 
 609.9
Resolution (Å) ........................................................40.0–3.0 (3.1–3.0)
No. of unique reflections .......................................119,617 (8,285)
Completeness (%) ..................................................72.3 (50.5)
Average I/sigma.......................................................6.5 (2.5)
Rmerge (%)................................................................15.4 (44.3)
Refinement ..............................................................CNS, version 1.2
No. of atoms (protein/solvent/DNA) ...................4,117/12/25
Average B factors (Å2) ..........................................61.87
Rcryst/Rfree (%) .........................................................27.5/28.8
RMSD bonds (Å) and angles (degrees) ..............0.009 and 1.48
Ramachandran plot
Most favorably allowed (%) ..............................92.5
Additionally allowed (%)...................................7.5
a Values in parentheses are for the highest resolution. CNS, crystallography
and NMR system (6). Rmerge 
 Ihkl  Ihkl/Ihkl  100, where Ihkl is the
intensity of an individual hkl reflection and Ihkl is the mean intensity for all
measured values of this reflection; the summation is over all equivalent intensi-
ties. Rcryst 
 Fobs  Fcalc/Fobs  100, where Fobs and Fcalc are the
amplitudes for the observed and calculated reflections, respectively. Rfree was
calculated with the 5% of reflections excluded from the data set during refine-
ment.
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the cryoreconstructed density map and a map generated from
structure factors calculated from the docked AAV1 crystal
structure-based polyalanine model using the Mapman program
(31). The docked model provided information on the C-
positions of five of the six amino acids (418, 531, 584, 598, and
642) that differ between AAV1 and AAV6 in the C-terminal
regions of VP3 (Fig. 1C and D). The side chain orientations
and potential interactions of these residues could not be de-
termined from the cryoreconstructed structure but were ob-
tained from the X-ray crystal structure.
The AAV6 crystal structure was determined to 3.0-Å reso-
lution (Table 2). The refinement and molecular geometry sta-
tistics are consistent with those reported for other members of
the Parvoviridae as well as structures determined for other
virus families at comparable resolution, as reported on the
VIPERdb website (http://viperdb.scripps.edu/). As has been
previously reported for other AAV capsid structures, the N-
terminal region of VP2 and the first 15 amino acids of VP3
were unresolved in both the cryo-EM and X-ray structures (23,
36, 37, 47, 52, 66, 73). In all of these AAV structures, only the
overlapping C-terminal VP (520-aa) region common to
the VP1, VP2, and VP3 sequence is unambiguously resolved.
The lack of ordered density for the VP N termini in the AAV6
VLPs used in this study likely results from the low copy num-
ber of VP2 (5 copies) and the fact that the VP3 N terminus
likely adopts different conformations, two factors which are
incompatible with the icosahedral symmetry imposed during
the structure determination procedures. The C-terminal 519
amino acids (amino acids 218 to 736, VP1 numbering) com-
mon to VP2 and VP3 (hereafter referred to as VP3) were
unambiguously assigned in the averaged AAV6 electron-den-
sity map (Fig. 2A and B). This same stretch of amino acids was
fitted into the cryoreconstructed density map (Fig. 1B to D).
The structural topology of the AAV6 VP3 is similar to that
previously reported for other parvoviruses, with a conserved
eight-stranded -barrel (BIDG-CHEF sheets) core that
forms the contiguous capsid and an  helix (A, residues 290
to 302, VP1 numbering) located on the wall of the depression
surrounding the icosahedral 2-fold axes (23, 37, 47, 73) (Fig.
2C). A tubular density feature consistent with helix A was
FIG. 1. AAV6 structure. (A) Surface representation of the AAV6 cryoreconstructed image at 9.7-Å resolution. The capsid surface density is
shown as a radially colored, depth-cued image (low to high radii, pink to gray). Selected icosahedral 2-fold (2f), 3-fold (3f), and 5-fold (5f) axes
of the capsid are indicated by arrows. (B) Cross-sectioned slab from the cryo-EM density map (gray isosurface) with the docked C- backbone of
the polyalanine model (residues 218 to 736, pink) derived from the AAV1 crystal structure. Dashed arrows indicate the approximate locations of
icosahedral axes of symmetry. (C) Coil representation of an AAV6 VP backbone trace (pink) showing the locations of the five amino acids (pink
spheres) within VP3 that differ between AAV1 and AAV6. The first and last letters in each residue label refer to AAV6 and AAV1, respectively.
(D) A trimer of AAV6 VPs (pink, green, and blue) showing the symmetry-related clustering of the differing residues (spheres) shown in panel C
and colored according to the monomer in which they reside. These residues cluster near the icosahedral 3-fold axes in both the interior (residues
418 and 642) and exterior (residues 531, 584, and 598) surfaces of the capsid. The view is approximately down the icosahedral 3-fold axis.
Approximate positions of icosahedral 2-, 3-, and 5-fold-symmetry axes of the capsid are depicted as filled ovals, triangles, and pentagons,
respectively, in panels C and D. Panels A and B were generated using the Chimera program (53), and panels C and D were generated using the
PyMol program (14).
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also observed in the cryoreconstructed density map (data not
shown). The capsid surface is formed by loop structures in-
serted between the  strands (Fig. 2C). These loops also con-
tain small stretches of  structure (Fig. 2C). Comparisons of
the previously determined AAV crystal structures identified
regions of variable conformation (VRI to VRIX) in these
loops (23). The VRs are spread throughout the VP3 structure
but are clustered on the capsid surface (23). These regions also
differ between AAV6 and the other AAVs, in particular,
AAV4 (Fig. 3A; see Table S1 in the supplemental material).
These VRs contribute to phenotypic differences, such as re-
ceptor attachment, transduction efficiency, and antigenic reac-
tivity, between the AAVs (10, 23, 37, 47, 52, 66, 73). The
conserved DE and HI loops (Fig. 2C and 3A), between the
DE and HI strands, respectively, play essential structural
and functional roles in the life cycle of the AAVs and other
parvoviruses. The DE loops in five, symmetry-related mono-
mers interact and form the channel at the 5-fold axis through
which genomic ssDNA is postulated to be packaged (35). This
is also where a phospholipase A2 (PLA2) domain, located
within the VP1 unique N termini, is proposed to be external-
ized during cellular trafficking (reviewed in reference 10) (35).
FIG. 2. Crystal structure of AAV6. (A and B) Sections of the 2Fo  Fc electron-density map (gray mesh) of AAV6, contoured at 1.0	, for two
of the residues (residue 584 in panel A and residue 642 in panel B) that differ between AAV6 and AAV1. The AAV1 (purple) and AAV6 (atom
type) coordinates are shown in stick form. (C) Ribbon diagram representation of AAV6 VP3 monomer (ordered residues 218 to 736), with labels
highlighting the conserved -barrel core motif (BIDG-CHEF, pink) and the A helix (blue). Loop regions (orange) between the core  strands
also contain small stretches of -strand structure (pink). The DE and HI loops are labeled. Approximate positions of icosahedral 2-, 3-, and
5-fold-symmetry axes in the capsid are depicted with filled symbols, as described in the legend to Fig. 1. Positions of the purine (Pu) and cytosine
(Cyt) NT bases that are ordered in the averaged density map are shown and labeled. (D) The conserved nucleotide binding pocket, showing the
ordered densities interpreted as a deoxyadenylate and cytosine (labeled), close to the 3-fold axis (see panel C). The deoxyadenylate and cytosine
molecules are shown inside the Fo  Fc difference density map (dark gray mesh) and contoured at 3.0	. AAV6 amino acids within 2.4 Å to 5.0
Å of the ordered density are shown and labeled; residue D609 has been omitted for clarity. (E) Comparison of nucleotide binding pocket in AAV3
(yellow), AAV4 (black), and AAV6 (pink) crystal structures. This region (structure and DNA) is also conserved in AAV8 (data not shown). AAV6
amino acid positions are labeled. This figure was generated using the PyMol program (14).
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Structural variation is observed at the top of the DE loop (Fig.
3A, VRII), consistent with dynamics which might be required
for genome packaging or the PLA2 externalization (34, 35).
The HI loop lines the floor of the depression around the
icosahedral 5-fold axes and is implicated in capsid assembly as
well as capsid dynamics associated with receptor attachment
(16, 38).
In addition to the VP3 structure and solvent molecules,
densities consistent with a purine NT and a pyrimidine base
were observed in the AAV6 VLP capsid structure, despite the
fact that these particles should be empty (devoid of DNA). The
purine base, assigned as an adenine due to the lack of a C-2
amino group density, is located in a conserved DNA binding
region and occupies the same position as the bases previously
reported in the crystal structures of AAV3, AAV4, and AAV8
(23, 37, 47) (Fig. 2D and E; the structure of AAV8 is not
shown). The conserved binding region contains amino acids
E417, V419, P420, D609, H630, P631, and S632, which are
capable of forming polar and hydrophobic interactions with
the NT and sandwich the bases between the two prolines (Fig.
2D and E; residue D609 is not shown). However, in AAV6, the
orientation of the base as modeled into the Fo  Fc map is
rotated 180° about the plane of the base relative to the bases
built into the other AAV structures due to the position of the
density interpreted as the deoxyribose sugar (see Fig. S1A in
the supplemental material). In the 2Fo  Fc Fourier map
(calculated before initial NT model building), a dual position
of the density interpretable as the deoxyribose was observed,
whereas the densities interpretable as the base and phosphate
groups overlap with positions observed for the other AAV NTs
(see Fig. S1B in the supplemental material). The dual orien-
tation of the sugar portion of this ordered NT suggests that
both orientations can occur with equal probability. The over-
lapping position of the base within the conserved binding
pocket suggests that its interactions with the surrounding
amino acids dictate the ordering of this nucleotide. The obser-
vation of a single sugar conformation in the Fo  Fc Fourier
density map (see Fig. S1A in the supplemental material) sug-
gests a higher propensity for the orientation modeled inside
the AAV6 VLPs.
Five angstroms from the purine base, a second base, cytosine
(assigned on the basis of the absence of methyl group density
at the C-5 position of the pyrimidine ring), is ordered in a
position proximal to the 3-fold axis (Fig. 2C). No sugar or
FIG. 3. Comparison of available AAV crystal structures. (A) Superposition of the VP3 monomer structures of AAV1 (purple), AAV2 (blue),
AAV3 (yellow), AAV4 (red), AAV6 (pink), and AAV8 (green). Common variable regions VRI to VRIX (as defined in reference 23) are labeled
with Roman numerals. The DE and HI loops are labeled. Approximate positions of icosahedral 2-, 3-, and 5-fold axes are depicted as described
in the legend to Fig. 1. (B and C) Close-up views of VRI and VRIV, respectively. This figure was generated using the PyMol program (14).
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phosphate groups were observed for this base, which interacts
with the main chain of H630. This histidine is conserved in
representative clade members of the AAVs (Fig. 2E), but
despite this conservation, the density for this base was not
reported in the AAV3 crystal structure (37), nor was it ob-
served in our structures of AAV4 and AAV8 (23, 47). There is
no indication that this cytosine base and the purine NT are
components of a single DNA chain.
Significantly, like the AAV6 structure, that of AAV8 was
also determined from baculovirus/Sf9-expressed VLPs pro-
duced in the absence of the rep ORF. These observations
support a proposal that the AAVs are able to package frag-
ments of host cellular DNA in the absence of Rep proteins
(38). A similar packaging of cellular genomic material is com-
monly observed for RNA viruses expressed in a heterologous
system, most likely due to a requirement for interaction with
nucleic acid for capsid assembly (20). For bacteriophage
X174, a small ssDNA virus that packages a genome similar in
size to those of parvoviruses, in virions, subgenomic pieces of
DNA are also observed in empty capsids and are also likely
required to facilitate capsid assembly (44). DNA packaging is
not required for the assembly of autonomous parvovirus VLPs,
as reported for minute virus of mice (29, 34), but the AAV
observations suggest that it may play a role for the dependovi-
ruses, though this remains to be verified.
The lower occupancy (0.5) of the AAV6 bases, relative to
the surrounding protein (as was reported for AAV8 [47]), is
consistent with the expected lack of icosahedral symmetry for
NTs ordered within VLPs. Indeed, only a single copy of the
ssDNA genome is packaged into wild-type virions, and thus,
the same NT/base cannot be ordered in all 60 sites within the
capsid, unless it is part of a conserved DNA sequence repeated
60 times and forming specific interactions with the capsid. Such
a conserved DNA sequence has not been reported for the
AAVs. Given occupancy of less than one, the strict NCS uti-
lized for electron-density averaging during the structure deter-
mination would be expected to result in reduced sigma for
NT/base density at each averaging cycle and eventual loss of
signal. Thus, the unexpected observation of ordered DNA den-
sity inside AAV6 and other AAVs suggests the presence of a
common DNA recognition motif inside the capsid directly
under the 3-fold axes (Fig. 2C). The fact that the recognition
site amino acids are conserved in most AAV sequences and all
the structures determined to date suggests an important func-
tion for this DNA interaction in the life cycle of the viruses,
such as a role in capsid stabilization or assembly.
Comparison of the AAV6 structure to structures of other
AAVs pinpoints capsid regions that control receptor attach-
ment and transduction efficiency. Superposition of the AAV6
structure with those available for AAV1 to AAV4 and AAV8
using the SSM application in the Coot program (18) shows
differences (stretches of two or more amino acids with C-
positions that are 1.0 Å apart between two serotypes [23])
with (i) AAV2 at VRI, VRII, VRIV, VRV, and VRVII; (ii)
AAV3 at VRI, VRII, VRIV, VRVI, VRVII, and VRIX; (iii)
AAV4 at VRI to VRIX; and (iv) AAV8 at VRI, VRII, VRIV,
VRV, and VRVII (Fig. 3A; see Table S1 in the supplemental
material). Variable regions I and IV were commonly divergent
in conformation between AAV6 and these four AAVs (Table
3; Fig. 3B and C). The amino acids that form these two surface
loops are also highly divergent between the representative
members of the AAV clades (52). AAV1 and AAV6 are 99%
identical and superimpose with an RMSD of 0.33 Å, and they
exhibit the lowest difference between the C- positions of
residues in their VRIV regions (Table 3; Fig. 3A and C).
AAV6 is the most structurally diverse from AAV4, with which
it shares the lowest degree of sequence homology (59% com-
pared to 80 to 99% with the other AAVs; Table 3). For exam-
ple, the C- positions of amino acids in VRIV differ from 1.0
to 14.6 Å, though the structures superimpose with an overall
RMSD of 0.94 Å. AAV6 and AAV2 (83% identical) superim-
pose with an RMSD of 0.67 Å, and the C- positions in VRIV
differ between 1.3 and 4.9 Å (Table 3).
The AAV VRs cluster on the capsid surface in the raised
regions between the icosahedral 2- and 5-fold axes (VRs I, III,
and IX) and on the wall (VRs VI and VII) and top (VRs IV,
V, and VIII) of the protrusions surrounding the icosahedral
3-fold axes (23). Significantly, VRI and VRIV (Fig. 3B and C)
have been shown to play a role in AAV tissue transduction and
antigenic recognition (41, 59). These reports suggest that struc-
tural heterogeneity, in addition to sequence variation, confers
these capsid-associated functions. The observation that VRIV
adopts slightly different conformations in AAV1 and AAV6
may be related to this loop being the least-ordered region in
the AAV6 structure. Atoms in the amino acids at the top of the
loop exhibit high-temperature factors, consistent with high
thermal motion and minor conformation variation compared
to those for AAV1.
To obtain a more detailed analysis of the structural deter-
minants that dictate differences in receptor attachment and
tissue transduction in the highly homologous AAV1 and
AAV6, we superimposed the AAV1 crystal structure (Govin-
dasamy and Agbandje-McKenna, unpublished) onto the re-
fined AAV6 structure in the electron-density map. This en-
abled the visualization of the positions of five of six amino acids
(AAV1 and AAV6 amino acids E418D, E531K, F584L,
A598V, and N642H) that differ between the AAV1 and AAV6
VPs (F584L and N642H are shown in Fig. 2A and B, respec-
tively). Amino acid 129 (VP1 numbering) in the VP1 unique
region was not present in the VP2/VP3 VLP construct used for
this structure determination. Three of the ordered residues
(531, 584, and 598) are located on the capsid surface, at (V598)
or close to (K531 and L584) the icosahedral 3-fold-symmetry
axes (Fig. 4A), whereas D418 and H642 are located on the
interior surface of the capsid, below the same capsid region
(Fig. 4B). Residues D418 and H642 are located in structurally
conserved VP regions, whereas surface residue 531 is located
in VRVI, residue 584 is located in VRVIII, and residue 598 is
TABLE 3. RMSD in C- position between AAV6 and the available





VR C- distance ranges (Å)
Overall VRI VRIV
1 99 0.33 1.3–1.8
2 83 0.67 1.2–5.7 1.3–4.9
3 86 0.57 1.7–5.8 1.3–6.4
4 59 0.94 0.9–6.8 1.0–14.6
8 80 0.57 1.3–7.4 1.4–2.4
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close to VRVIII. The localization of these five amino acids at
or surrounding the icosahedral 3-fold axes, with K531 being
near the icosahedral 2-fold axes in VRVI, highlights the im-
portance of these capsid regions in AAV biology with respect
to receptor attachment and transduction efficiency. The sur-
face-exposed amino acid differences indicate potential sites for
conferring the differential receptor recognition and transduc-
tion properties of AAV1 and AAV6 that are associated with
entry or preuncoating interactions. The residues on the inside,
with 418 in the vicinity of the DNA binding region (Fig. 4D)
are unlikely to play a role in receptor attachment but could be
involved in postentry/uncoating events that affect transduction
efficiency.
With respect to receptor attachment, residue K531 in AAV6
(E531 in AAV1) has been reported to be important for its HS
binding properties, and an E531K mutant of AAV1 shows
strong affinity for HS and also confers liver cell transduction
(69), identifying a position at the base of the protrusions and
close to the depression at the icosahedral 2-fold axes (Fig. 4A)
that confers this phenotype. None of the mutations in AAV1
converting the remaining five amino acids which differ from
those in AAV6 to the type found in the latter virus conferred
an HS binding phenotype (70). A novel primate AAV variant,
AAV(VR-942), which also uses HS as a primary receptor,
contains a K528 residue that is predicted to be structurally
equivalent to the AAV6 K531 residue (57) (Table 4). AAV2
also binds HS (60) but lacks this basic residue and, instead,
utilizes two critical residues, R585 and R588, along with R484,
R487, K527, and K532 (minor contributors) (AAV2 VP1 num-
bering) (Table 4) for this interaction (32, 38, 49, 50, 60). Except
for R487, these residues form a basic footprint on the surface
(Fig. 5B) of the AAV2 capsid on the inner face of the protru-
sions surrounding the 3-fold axes. Interestingly, AAV1 and
AAV6 contain basic residues R485, R488, K528, and K533
(equivalent to R484, R487, K527, and K532, respectively, in
AAV2) in the equivalent region of the mapped AAV2 HS
binding site, plus R576 and H597 (Fig. 5A, B, and D). A basic
region is created on the AAV1 and AAV6 capsid surface by
residues R485, R576, and H597 close to the 3-fold axis and is
missing in AAV2, which contains R484, Q575, and N596 at the
structurally equivalent positions (Fig. 5A, B, and D). However,
a role in HS binding has not been reported for R576 and H597.
On the other hand, in AAV6, K531 is located adjacent to R488
(equivalent to AAV2 R487, but is now surface exposed), K528,
and K533, which creates a second continuous basic patch on
the capsid surface, whereas in AAV1, E531 creates a gap in
this patch (Fig. 5A and D). Hence, this continuous, basic re-
gion is likely sufficient for and the determinant of HS binding
by AAV6. AAV5, which binds sialic acid, is missing all these
basic residues, except for R471, which is equivalent to AAV6
R485 (Table 4).
FIG. 4. Locations of amino acid differences in AAV1/AAV6 cap-
sids. (A) Surface representation of an AAV6 VP3 trimer viewed from
outside approximately along a 3-fold axis (middle) with the white
boxed section rotated by 90° (top). The monomers are colored pink
(reference), green (3-fold), and blue (3-fold) (as in Fig. 1B), with the
differing AAV1/AAV6 amino acids colored in yellow. Residues
K531E, L584F (3f-L584 is from a 3-fold related monomer), and V598A
(first letter, AAV6; second letter, AAV1) are located on the capsid
surface. The panel on the top shows the close proximity of residues 531
and 584 at the base of the 3-fold protrusions facing the icosahedral
2-fold axis. (B) Same as panel A, but rotated 180° to show the location
of residues D418E and H642N on the interior surface of the capsid.
The approximate position of the 3-fold axis (3f axis) is indicated with
a solid arrow in all three panels. Approximate positions of icosahedral
and 2- and 5-fold symmetry axes on the capsid are depicted as de-
scribed in the legend to Fig. 1. This figure was generated using the
PyMol program (14).
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In addition to these basic residues, the juxtaposition of acidic
residues on the capsid surface and their interactions with
amino acids in the vicinity of the mapped basic HS binding
residues appears to be important for the binding of this glycan
by AAV serotypes. Mutation of an acidic residue, D532 to
N532, adjacent to K533 on the AAV6 capsid surface (Fig. 5D
and 6A), in an AAV variant derived by directed evolution from
AAV libraries, shH10, was reported to confer HS binding
dependence and sialic acid binding independence (Table 1) for
cellular transduction by the variant (33). In contrast, though
wild-type AAV6 binds HS, it can transduce cells in the absence
of HS but not in the absence of sialic acid (33, 58, 70). Residue
D532 is predicted to stabilize the surface loop containing K531
by means of electrostatic interactions with H527 and D562
(Fig. 6A), which are likely to be disrupted if the acid group at
position 532 is lost. This loop also contains K528 and K533,
which flank K531 on the capsid surface, as discussed above
(Fig. 5D and 6A). The D532N mutation reduces the negative
charge on the capsid and likely disrupts the D532-H527-D562
interaction; consequently, it could alter the conformation of
this loop and thus the cellular interactions of constituent res-
idues. The predicted loop-stabilizing interaction is conserved
in HS binding AAV2 through the interactions of E531-H526-
D561 and also E563 (Fig. 6B); thus, the stabilization is ex-
pected to be tighter in this virus. The side chain of AAV6
residue E564, with a C- position equivalent to AAV2 E563,
adopts a different orientation and does not participate in the
stabilizing interactions (Fig. 6C). The shH10 mutant has im-
proved HS binding compared to that of wild-type AAV6 and
exhibits an improved transduction phenotype. AAV6, on the
other hand, binds HS more weakly than AAV2 but also exhib-
its better transduction properties. Thus, binding affinity alone
does not control transduction efficiency (33). Also, improved
HS binding of the AAV6 D532N mutant nullified the virus’s
need for sialic acid, although it still transduced cells that con-
tain sialic acid. These observations highlight the complex na-
ture of cellular interactions that control cellular transduction
mechanisms.
Further support for the role of acidic residues in HS binding
was reported by Wu et al., who found that alanine scanning
mutagenesis of acidic AAV2 residues 561-DEEE-564 to 561-
AAAA-564 resulted in a noninfectious HS-negative (HS)
mutant (69). AAV6 residue D562 is not on the capsid surface
but is structurally equivalent to AAV2 D561, which along with
E563 and E531 participates in interactions which stabilize the
basic residues involved in AAV HS binding (Fig. 6C), as dis-
cussed above. A disruption of the D561 and E563 interactions
with neighboring residues, which is predicted to occur when
these acidic residues are mutated to alanine in AAV2, is likely
involved in the HS phenotype of the 561-AAAA-564 mutant.
Interestingly, AAV2 E531, D561, and E563 are contained in
two highly conserved acidic stretches of amino acids in the
representative AAV clade members, with the exception of
clonal isolates AAV4 and AAV5 (52). The above observations
suggest that their interactions are important for stabilizing the
configuration of HS binding regions on the AAV2 capsid as
well as the AAV6 capsid.
The region of the AAV capsid required for interaction with
sialic acid has not been structurally mapped, but mutagenesis
studies with AAV5 suggest the involvement of A581 at the
icosahedral 3-fold axes (19) (Fig. 5C). An alanine is conserved
at the equivalent positions in AAV1, AAV2, and AAV6 (A592,
A591, and A592, respectively) (Table 4; Fig. 5A to D). Of note,
the region at or immediately adjacent to the icosahedral 3-fold
axis is hydrophobic in AAV1, AAV5, and AAV6, which bind
sialic acid, and polar in AAV2, which does not (Fig. 5). Thus,
if this is a conserved, sialic acid recognition site among the
AAVs, the V598A difference between AAV6 and AAV1,
which, along with V582 and A592, forms a continuous hydro-
phobic surface at the 3-fold axes (Fig. 5A and D), may be
involved in the sialic acid binding interaction of both viruses.
Both viruses are reported to have common sialic acid linkage
recognition (71), and thus, if residue 598 exhibits a serotype-
specific phenotype in transduction, it is unlikely to be due to
this interaction.
Efforts to engineer AAV variants with improved/tissue-spe-
cific transduction properties have led to chimeric AAV1 and
AAV6 vectors that show differential lung epithelial cell trans-
duction efficiency dependent on which residues in the two
serotypes are located at VP1 unique position 129 and within
the common VP3 sequence (39, 40). The AAV6 F129L muta-
tion (AAV6.2 in Table 1) confers 2-fold better transduction in
airway epithelium (40) compared to the parental serotype and
AAV6 K531E (AAV6.1 in Table 1), which eliminates HS bind-
ing, confers an AAV1 transduction phenotype that is reduced
compared to that of the parental AAV6. This observation
suggests that amino acids at both the 129 and 531 positions
affect cellular transduction. Residue 129, located in the VP1
unique region, is part of a PLA2 domain in the parvoviruses
that is predicted to be located inside the assembled capsid but
that later becomes externalized through the 5-fold channel
during capsid trafficking through the endocytic pathway. This is
TABLE 4. Comparison of residues reported to be involved in heparan sulfate and sialic acid binding for AAV6, AAV1, AAV2, AAV5, and





Residue at position (AAV6 numbering):
485 488 528 531 533 586 589 592
HS/Sa 6 R R K K K S T A
S 1 R (485)b R (488) K (528) E (531) K (533) S (586) T (589) A (592)
HS 2 R (484) R (487) K (527) E (530) K (532) R (585) R (588) A (591)
S 5 R (471) G (474) L (515) S (518) N (519) S (575) T (578) A (581)
HS VR942 R (482) R (485) K (525) K (528) K (530) N (583) A (586) T (589)
a HS, heparan sulfate; S, sialic acid.
b Numbers in parentheses are based on VP1 numbering for the respective serotypes.
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FIG. 5. Comparison of AAV surface residues. Schematic Roadmap projections (72) of surface residues in a portion of the icosahedral asymmetric
unit for crystal structures of AAV1 (A), AAV2 (B), AAV5 (C), and AAV6 (D) are shown. The area occupied by each amino acid residue correlates to
surface exposure when the capsid is viewed down an icosahedral 2-fold axis. The boundary for each residue is shown in black, and the colors correspond
to acidic (red), basic (blue), polar (yellow), and hydrophobic (green) residues. Dashed outlines highlight regions proposed to play a role in glycan binding
by the respective serotypes. Residues are labeled by type and number. The icosahedral 3-fold axis is depicted by the filled triangle.
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purported to aid endosomal escape for nuclear localization
and subsequent genome replication (35). Residue 531, as dis-
cussed above, facilitates HS binding in AAV6. Thus, residues
129 and 531 are likely involved in postentry events and recep-
tor recognition, respectively. Consistent with this suggestion, a
mutant containing F129L and K531E (Table 1, AAV6R2) had
the reduced transduction phenotype of the virus with the single
K531E mutation (40), indicating that the K531E mutation
functions early in infection, prior to the step affected by amino
acid F129L.
Li et al. used directed evolution from an AAV library to
identify chimeric human airway epithelia (HAE) transducing
vectors, HAE-1 and HAE-2 (Table 1), which contain mostly
AAV1 and AAV6 sequences and which have improved trans-
duction efficiency relative to that of the parental serotypes
(39). HAE-1 contains AAV1 residues 1 to 583/641 to 736 and
AAV6 residues 584 to 640, and HAE-2 contains AAV9 resi-
dues 1 to 30/104 to 193, AAV1/AAV6 residues 31 to 103,
AAV6 residues 194 to 641, and AAV1 residues 642 to 736. The
reported transduction efficiencies for these viruses compared to
the those of the parental serotypes were in the order AAV1/
AAV9  AAV6  HAE-1  HAE-2, with HAE-1 and HAE-2
showing 3- to 4-fold and 2-fold improved transduction
compared to that of AAV1 and AAV6, respectively. HAE-1
contains AAV1 residue L129 (not observed in the crystal struc-
tures), capsid surface residue E531, and interior residues E418
and N642, with AAV6 contributing surface residues L584 and
V598 (Table 1). Thus, L584 and V598 confer the 3-fold
improvement in HAE-1 transduction compared to that of
AAV1. The improvement in transduction relative to that in
AAV6 could be due to the L129 from AAV1, as discussed
above. HAE-2 contains the equivalent of AAV1 L129 (con-
tributed from AAV9) and interior residue N642 from AAV1
and AAV6 capsid surface residues, K531, L584, and V598, as
well as interior residue D418 from AAV6 (Table 1). For this
vector, the AAV6 K531 residue likely combines with the L129,
L584, and V598 residues of HAE-1 to achieve the further
improvement in transduction compared to that of the parental
viruses and HAE-1. Both chimeras were observed to bind
equally to the apical surface of HAE, suggesting that their
difference in transduction was postentry, consistent with an
intracellular step in the viral life cycle at which L129 is critical.
A functional role for the interior residues, 418 and 642, is yet
to be defined.
In summary, this comparative analysis of AAV1 and AAV6
highlights key AAV residues that control host interactions,
including receptor recognition and attachment as well as
postentry events, which enable successful infection and im-
proved cellular transduction. These results should facilitate
further molecular characterization and manipulation of AAV
vectors for improved tissue-specific targeting.
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FIG. 6. Stabilizing interactions for the K531 loop. (A) Residues
D532, H527, and D562 that form electrostatic interactions at the base
of the loop containing basic residues K528, K531, and K533 are shown
along with neighboring residues R485 and R488, equivalent to R484
and R487, respectively, involved in HS binding by AAV2. 3f-L584 is
contributed from a 3-fold (3f) related VP3 monomer. The residues (in
stick form) are colored according to atom type: carbon, yellow; nitro-
gen, blue; and oxygen, red. Dashed lines indicate the distance between
interacting residues. Disruption of the D532-H527-D562 interaction by
a D532N mutation is predicted to alter the conformation of the basic
loop and in turn could alter AAV6 HS binding properties. (B) AAV2
residues E531, H526, D561, and E563 that form electrostatic interactions
which stabilize an equivalent surface loop in this serotype containing
residues K527, E530, and K532 and the neighboring amino acids, R484
and R487, involved in HS binding. Mutation of D561 and E563 to alanine
disrupts HS binding in AAV2. 3f-L583 is contributed from a 3f VP3
monomer. Residues are colored as in panel A. (C) A superimposition of
the residues shown in panels A and B with the AAV6 amino acids
(labeled in black) shown according to atom type, as described for panels
A and B, and those for AAV2 are colored blue (labeled in blue). This
figure was generated using the PyMol program (14).
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